Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PLUR
stocks logo

PLUR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Valuation Metrics

The current forward P/E ratio for Pluri Inc (PLUR.O) is -1.30, compared to its 5-year average forward P/E of -1.23. For a more detailed relative valuation and DCF analysis to assess Pluri Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.23
Current PE
-1.30
Overvalued PE
-0.05
Undervalued PE
-2.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.49
Current PS
0.00
Overvalued PS
12.24
Undervalued PS
-5.26
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PLUR News & Events

Events Timeline

(ET)
2025-11-11
08:06:38
Pluri Unveils Cellav Health and Aesthetics Initiative
select
2025-11-10 (ET)
2025-11-10
08:12:12
Pluri Engages in Multiple Global Partnerships
select
2025-10-08 (ET)
2025-10-08
09:09:39
Coffeesai, a subsidiary of Pluri, reveals strategic partnership for production.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
11-11Newsfilter
Pluri Collaborates with Miss Universe Skincare to Launch Exosome-Enhanced Regenerative Skincare Line

  • Launch of Cellav: Pluri Inc. has launched Cellav Health and Aesthetics Ltd., a subsidiary focused on developing advanced exosome-based technologies for medical aesthetics using Pluri's proprietary 3D cell expansion platform.

  • Collaboration with Miss Universe Skincare: Cellav has secured a partnership with Miss Universe Skincare to co-develop a new line of cell-based skincare products, with the first product expected to launch in the first half of 2026.

  • Market Potential: The beauty market is projected to reach $194.05 billion by 2032, highlighting the significant growth opportunity for Cellav's innovative skincare solutions.

  • Leadership and Vision: Cellav is led by CEO Katty Dowery, who emphasizes the integration of advanced biotechnology into everyday beauty products, aiming to make regenerative science accessible and impactful.

[object Object]
Preview
9.5
08-20Yahoo Finance
Plurilock Security Inc. Announces Financial Results for the Second Quarter of Fiscal Year 2025

  • Financial Performance: Plurilock Security Inc. reported a 159% increase in Critical Services revenue year-over-year and a 42% improvement in Adjusted EBITDA loss for Q2 2025 compared to the same period in 2024.

  • Revenue Breakdown: Total revenue for Q2 2025 was CAD 16.4 million, with significant contributions from professional services and software sales, while hardware sales decreased as a percentage of total revenue.

  • Operational Highlights: The company secured new contracts worth CAD 5.9 million across federal and public sector clients and expanded its presence in NATO and other international defense markets.

  • Future Outlook: Plurilock aims to continue its growth strategy focused on higher-margin offerings and is well-positioned to benefit from increased government spending in cybersecurity and defense sectors.

[object Object]
Preview
7.5
05-27Newsfilter
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

  • Partnership Announcement: BrainStorm Cell Therapeutics has signed a Letter of Intent with Minaris Advanced Therapies to manufacture its investigational therapy NurOwn® for an upcoming Phase 3b clinical trial, enhancing its manufacturing capabilities in the U.S.

  • Therapeutic Overview: NurOwn® utilizes autologous mesenchymal stem cells to produce neurotrophic factor-secreting cells aimed at treating neurodegenerative diseases like ALS, and has received Orphan Drug designation from both the FDA and EMA.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Pluri Inc (PLUR) stock price today?

The current price of PLUR is 3.26 USD — it has decreased -4.68 % in the last trading day.

arrow icon

What is Pluri Inc (PLUR)'s business?

Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.

arrow icon

What is the price predicton of PLUR Stock?

Wall Street analysts forecast PLUR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLUR is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Pluri Inc (PLUR)'s revenue for the last quarter?

Pluri Inc revenue for the last quarter amounts to 316.00K USD, decreased -3.07 % YoY.

arrow icon

What is Pluri Inc (PLUR)'s earnings per share (EPS) for the last quarter?

Pluri Inc. EPS for the last quarter amounts to -0.65 USD, decreased -39.81 % YoY.

arrow icon

What changes have occurred in the market's expectations for Pluri Inc (PLUR)'s fundamentals?

The market is revising No Change the revenue expectations for Pluri Inc. (PLUR) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -35.06%.
arrow icon

How many employees does Pluri Inc (PLUR). have?

Pluri Inc (PLUR) has 106 emplpoyees as of December 05 2025.

arrow icon

What is Pluri Inc (PLUR) market cap?

Today PLUR has the market capitalization of 30.17M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free